Early Clinical Experience with Molnupiravir for Mild to Moderate Breakthrough COVID-19 among Fully Vaccinated Patients at Risk for Disease Progression

Information on the efficacy and safety of molnupiravir in daily clinical practice is very scarce. We aimed to describe the clinical characteristics and outcomes of fully vaccinated patients with mild to moderate breakthrough COVID-19 treated with molnupiravir between January 2022 and February 2022....

Celý popis

Podrobná bibliografie

Hlavní autoři:	Antonio Vena, Luca Traman, Martina Bavastro, Alessandro Limongelli, Chiara Dentone, Federica Magnè, Daniele Roberto Giacobbe, Malgorzata Mikulska, Lucia Taramasso, Antonio Di Biagio, Matteo Bassetti
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2022-07-01
Edice:	Vaccines
Témata:	molnupiravir COVID-19 vaccines Intensive care unit admission
On-line přístup:	https://www.mdpi.com/2076-393X/10/7/1141
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!